An expert is one who knows more and more about less and less until he knows absolutely everything about nothing

Saturday, March 19, 2016

richilemmoma in continuity with pigmented basal cell carcinoma; with dermatoscopy and dermatopathology

Moayad Al Kaptan, Joseph Kattampallil, Cliff Rosendahl A case of trichilemmoma in continuity with a pigmented basal cell carcinoma is presented with dermatoscopy and dermatopathology. The distinction between the two lesions was evident dermatoscopically and was confirmed dermatopathologically. While trichilemmoma has been reported in association with...
Ahmed Alzaraa, MRCS,* George D.H. Thomas, MD,† Alexander Vodovnik,MD,† Vijay K Modgill,FRCS Abstract: Merkel cell carcinoma is a rare skin neoplasm and has not been reported yet in a male breast. We present a case of 74-year-old patient who was referred to the breast clinic with a lump in his right breast, which led first to the core biopsy followed by radical...

Training needs of clinical research associates

ABSTRACT Clinical research is a relatively new field in our country that has seen very rapid growth in the last few years. Availability of personnel appropriately trained to the specific requirements of the role they will perform in clinical research is critical for capacity expansion. Our study attempts to understand the specific areas of knowledge and skills that are...

Top Cancer-Fighting Foods

Approximately one-third of all cancers are directly related to diet. To help prevent cancer, try making some of these foods that fight cancer a regular part of your die...

Friday, March 18, 2016

FDA Approves Antiplatelet Agent Kengreal (cangrelor) as Adjunct to Percutaneous Coronary Intervention

June 22, 2015 — The U.S. Food and Drug Administration today approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries, the blood vessels that supply blood to the heart. It is approved for adult patients undergoing percutaneous coronary intervention (PCI), a procedure used to open a blocked or...

FDA Approves Stiolto Respimat

Stiolto Respimat Generic Name: olodaterol and tiotropium bromideDate of Approval: May 21, 2015Company: Boehringer Ingelheim Pharmaceuticals, Inc. Stiolto Respimat is a combination of the long-acting beta2-adrenergic agonist olodaterol (Striverdi Respimat), and the anticholinergic agent tiotropium (Spiriva Respimat). The U.S. Food and Drug Administration (FDA) has...


About Blogger:

Hi,I,m Basim from Canada I,m physician and I,m interested in clinical research feild and web development.you are more welcome in our professional website.all contact forwarded to basimibrahim772@yahoo.com.


Let's Get Connected: Twitter | Facebook | Google Plus| linkedin

 

Subscribe to us